Soft Mist Inhalers Market - By Product Type (Disposable, Reusable), Age-Group (Adult, Pediatric), Application (Asthma, COPD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use & Global Forecast, 2024 – 2032

Soft Mist Inhalers Market - By Product Type (Disposable, Reusable), Age-Group (Adult, Pediatric), Application (Asthma, COPD), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End-Use & Global Forecast, 2024 – 2032

Soft Mist Inhalers Market Size

Soft Mist Inhalers Market size was valued at USD 184.6 million in 2023 and is expected to grow at a CAGR of 9.2% from 2024 to 2032. Rising prevalence of respiratory conditions, growing emphasis on home-based healthcare, and increasing demand for drug delivery devices are among the key factors propelling the market progression.

To get key market trends

  Download Free Sample

The rising prevalence of respiratory conditions such as asthma, COPD, and bronchitis worldwide is a significant driving force for market expansion. These conditions necessitate efficient inhalation therapy, making soft mist inhalers among the preferred choice for patient treatment. For instance, as per the American Lung Association’s data, in 2022, 11.7 million people, or 4.6% of adults, reported a diagnosis of COPD (chronic obstructive pulmonary disease, chronic bronchitis, or emphysema) in the U.S. Additionally, according to statistics reported by the Centers for Disease Control and Prevention (CDC), the overall prevalence of asthma among adults stood at 8.0% in 2021.
 

What are the growth opportunities in this market?

 Download Free Sample

Further, this increasing prevalence contributes to the growing demand for drug delivery devices such as soft mist inhalers, which in turn will fuel the industry growth. Furthermore, these devices play a vital role in ensuring the effective administration of medication, thereby improving patient outcomes and facilitating the advancement of personalized medicine approaches.

Soft mist inhalers (SMIs) are inhalation devices used to deliver medication directly into the lungs in the form of a slow-moving mist. Unlike traditional metered-dose inhalers (MDIs) or dry powder inhalers (DPIs), which deliver medication as aerosols or dry powders, soft mist inhalers produce a fine mist of medication that is propelled by mechanical energy.

Soft Mist Inhalers Market Trends

Soft mist inhalers are increasingly being used for a wide range of respiratory related indications due to consistent innovation in the therapeutic respiratory devices, such as improvements in dose accuracy, and portability, among others. These parameters are expected to enhance patient convenience and clinical outcome, thereby driving the market growth.

• The advancements in soft mist inhaler technology have enabled the development of novel formulations and smart inhalers that target specific lung areas and provide optimized drug delivery. These innovative formulations enhance treatment outcomes by ensuring precise drug targeting and efficient absorption in the lungs, resulting in increased product  demand in the market.
• Furthermore, researchers are investigating nanotechnology-based drug delivery systems to improve the effectiveness and safety of medications administered through soft mist inhalers. Utilizing nano-sized drug particles enhances solubility, bioavailability, and targeted delivery to the respiratory tract, thereby optimizing therapeutic outcomes, minimizing systemic side effects, and reducing the necessary dosage.

Soft Mist Inhalers Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

The market by product type is categorized into disposable and reusable. The reusable segment is anticipated to witness fastest market growth with a 10.1% CAGR over the projected timeline.

• Reusable SMIs may offer opportunities for customization and personalization, allowing patients to choose their preferred medication formulations and adjust dosages as needed. This customization can help improve treatment adherence and patient satisfaction.  
• Moreover, though reusable SMIs may have a higher initial cost compared to disposable inhalers, they can be more cost-effective in the long run. Patients with frequent inhaler use may find it more economical to invest in a reusable device, rather than purchasing multiple disposable inhalers over time.

The soft mist inhalers market by age group is categorized into adult and pediatric. The adult segment dominates the market with a revenue of USD 137.1 million in 2023.

• Adults are more likely to be exposed to environmental pollutants, occupational hazards, and lifestyle factors such as smoking, which can increase the risk of developing respiratory conditions. These factors contribute to the higher prevalence of respiratory conditions among adult population and increases the necessity of utilizing medication inhalers such as soft mist inhalers.  
• Moreover, respiratory conditions like asthma, chronic obstructive pulmonary disease (COPD), and bronchitis are more commonly found among adult population category than children, thus, leading to an increased reliance and demand for  soft mist inhalers within the adult age group.

Based on application, the soft mist inhalers market is categorized into asthma and COPD. The COPD segment dominates the market with a revenue of USD 109.9 million in 2023.

• Inhalation therapy is the preferred route of drug administration for managing COPD symptoms, as it allows for direct delivery of medications to the lungs, resulting in faster onset of action and lower systemic side effects compared to oral medications. Soft mist inhalers offer a user-friendly alternative to traditional inhalation devices, making them particularly suitable for COPD patients who may have difficulty using other inhalers due to coordination issues or reduced lung function.
• Additionally, soft mist inhalers equipped with user-friendly functionalities like breath-actuation mechanisms and dose counters play a crucial role in enhancing patient adherence to COPD treatment plans. These features simplify the inhalation process and offer visual feedback on medication usage, ultimately improving treatment adherence. Enhanced adherence translates to better treatment results, fewer exacerbations, and an overall improved quality of life for individuals living with COPD.

Learn more about the key segments shaping this market

 Download Free Sample

The soft mist inhalers market by distribution channel is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to reach USD 213.9 million by 2032.

• Hospital pharmacies play a vital role in supplying medications for treating acute respiratory conditions like asthma and COPD exacerbations. Soft mist inhalers are often prescribed in hospital settings to administer bronchodilators and other medications promptly, making hospital pharmacies the primary distribution channel for these inhalers.
• Furthermore, hospital pharmacies may offer access to specialized soft mist inhalers or formulations that aren't readily found in retail or online pharmacies. These specialized medications might be prescribed for patients with severe or refractory respiratory conditions necessitating advanced treatment options, thereby driving growth in this segment.

The soft mist inhalers market by end-use is categorized into hospitals and clinics, homecare settings, and other end-users. The hospitals and clinics segment held a leading market share with a revenue of USD 96.4 million in 2023.

• Hospitals and clinics offer a range of respiratory care services, catering to both inpatient and outpatient needs through emergency department visits, hospital stays, and outpatient clinic appointments. Soft mist inhalers are commonly prescribed in both settings to ensure consistent care for patients with respiratory conditions, making hospitals and clinics the primary end users for such products.
• Additionally, healthcare providers working in hospital and clinic environments may have preferences for specific soft mist inhalers based on clinical evidence, patient characteristics, and formulary considerations. Hospitals and clinics typically maintain stocks of medications preferred by physicians to meet the requirements of their patient population, thereby driving demand for these products further.

Looking for region specific data?

 Download Free Sample

North America soft mist inhalers market accounted for USD 81.1 million revenue in 2023 and is predicted to witness substantial market growth.

• There is a growing emphasis on personalized medicine and targeted therapies in North America, including the management of respiratory conditions. Soft mist inhalers allow for precise dosing and delivery of medications, enabling healthcare providers to tailor treatment regimens to individual patient needs. The focus on personalized medicine drives demand for soft mist inhalers as part of personalized treatment approaches for respiratory diseases.
• Moreover, reimbursement policies and healthcare coverage in North America often include coverage for inhaler medications, making them more accessible and affordable for patients. Favorable reimbursement policies encourage healthcare providers to prescribe soft mist inhalers as part of comprehensive respiratory treatment plans, driving demand for these devices.

Soft Mist Inhalers Market Share

The soft mist inhalers industry is Monopolistic in nature. Market leaders in the SMI sector may invest significantly in research and developments to enhance inhaler performance, improve drug delivery efficiency, and introduce novel functionalities such as connectivity and smart features.

Soft Mist Inhalers Market Companies

Some of the eminent market participants operating in the soft mist inhalers industry include

• Aero Pump G.m.b.H
• Boehringer Ingelheim
• Changzhou DSB Medical Co., Ltd.
• Merxin Ltd.

Soft Mist Inhalers Industry News

• In March 2024, Boehringer Ingelheim implemented a program to cap out-of-pocket costs for its inhaler products at USD 35 monthly. This initiative aims to reduce costs for patients who are under or uninsured, providing them with more affordable access to essential inhaler products. Additionally, this initiative may enhance the awareness about the product and available buying options as well as improve the company’s reputation in the market.  
• In January 2024, Recipharm AB, Medspray, and Resyca entered into an exclusive license agreement to develop nasally delivered drug products utilizing proprietary soft mist technology. This collaboration aims to advance the development of soft mist nasal delivery devices for single and combination drug products and also expand the company’s positioning in the market.

Soft mist inhalers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Product Type

• Disposable
• Reusable

Market, By Age Group

• Adult
• Pediatric

Market, By Application  

• Asthma
• COPD

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

Market, By End-use

• Hospitals and clinics
• Homecare settings
• Other end-users

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa